Advanced search×

European Journal of Pharmacology

Print ISSN
Electronic ISSN
Impact factor
Usage rank
Article count
Free count
Free percentage
PDFs via platforms
Ingenta, Sciencedirect, Gale, Proquest, CSA, and Rcgp

  1. Editorial Board
    Author(s) unavailable

    European Journal of Pharmacology 766:ii (2015)

  2. miR-100 suppresses mTOR signaling in hypoxia-induced pulmonary hypertension in rats

    European Journal of Pharmacology 765:565 (2015) PMID 26409044

    Mammalian Target of Rapamycin (mTOR) is involved in the proliferation and survival of pulmonary artery smooth muscle cells (PASMCs) in human pulmonary hypertension (PH) and animal PH models, and miRNAs are reported to play a key role in modulation of the proliferation of PASMCs. The pu...
  3. Suppressive effect of membrane-permeable peptides derived from autophosphorylation sites of the IGF-1 receptor on breast cancer cells

    European Journal of Pharmacology 765:24 (2015) PMID 26276395

    Insulin-like growth factor-1 (IGF-1) receptors play a crucial role in the biology of human cancer, making them an attractive target for anti-cancer agents. We previously designed oligopeptides containing the amino-acid sequences surrounding the autophosphorylation sites of the insulin ...
  4. Effect of combination therapy consisting of enalapril, α-lipoic acid, and menhaden oil on diabetic neuropathy in a high fat/low dose streptozotocin treated rat

    European Journal of Pharmacology 765:258 (2015) PMID 26291662

    We have previously demonstrated that treating diabetic rats with enalapril, an angiotensin converting enzyme (ACE) inhibitor, α-lipoic acid, an antioxidant, or menhaden oil, a natural source of omega-3 fatty acids can partially improve diabetic peripheral neuropathy. In this study we s...
  5. Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease

    European Journal of Pharmacology 765:284 (2015) PMID 26302060

    Oxyntomodulin is a hormone and a growth factor. It activates two receptors, the Glucagon-like peptide 1 (GLP-1) and the glucagon receptor. GLP-1 mimetics are on the market as treatments for type 2 diabetes and are well tolerated. These drugs have shown neuroprotective properties in ani...
  6. Reduction in renal blood flow following administration of norepinephrine and phenylephrine in septic rats treated with Kir6.1 ATP-sensitive and KCa1.1 calcium-activated K+ channel blockers

    European Journal of Pharmacology 765:42 (2015) PMID 26277325

    We evaluated the effects of K+ channel blockers in the vascular reactivity of in vitro perfused kidneys, as well as on the influence of vasoactive agents in the renal blood flow of rats subjected to the cecal ligation and puncture (CLP) model of sepsis. Both norepinephrine and phenylep...
  7. Synergistic antinociceptive interaction between palmitoylethanolamide and tramadol in the mouse formalin test

    European Journal of Pharmacology 765:68 (2015) PMID 26297302

    Pharmacological synergism has been used to obtain a higher efficacy using drug concentrations at which side effects are minimal. In this study, the pharmacological antinociceptive interaction between N-palmitoylethanolamide (PEA) and tramadol was investigated. The individual concentrat...
  8. Atractylenolide I protects mice from lipopolysaccharide-induced acute lung injury

    European Journal of Pharmacology 765:94 (2015) PMID 26297303

    Atractylenolide I (AO-I), one of the major bioactive components isolated from Rhizoma Atractylodes macrocephala, has been reported to have anti-inflammatory effects. In the present study, we investigated the protective effects of AO-I on acute lung injury (ALI) using LPS-induced ALI mo...
  9. Modulation of endoplasmic reticulum stress in Parkinson's disease

    European Journal of Pharmacology 765:154 (2015) PMID 26297973

    Parkinson's disease is a neurodegenerative disease characterized by the loss of dopaminergic neurons in the substantia nigra in the midbrain. However, the etiology of the reduction in dopaminergic neurons remains unclear. Recently, it has been suggested that oxidative stress, endoplasm...
  10. Current and future treatment strategies for iron overload cardiomyopathy

    European Journal of Pharmacology 765:86 (2015) PMID 26291660

    Iron overload cardiomyopathy is the major cause of death in transfusion-dependent thalassemia (TDT) patients. Growing evidence demonstrates that combined iron chelators, or the combination of an iron chelator with antioxidant(s) are effective in diminishing myocardial iron deposition a...